These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24956248)

  • 1. Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma.
    Goričar K; Kovač V; Dolžan V
    Pharmacogenomics; 2014 May; 15(7):941-50. PubMed ID: 24956248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.
    Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
    OMICS; 2015 Mar; 19(3):180-5. PubMed ID: 25748439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility.
    Zhang S; Chen H; Zhao X; Cao J; Tong J; Lu J; Wu W; Shen H; Wei Q; Lu D
    Oncogene; 2013 Jan; 32(2):242-50. PubMed ID: 22349819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.
    Senk B; Goricar K; Kovac V; Dolzan V; Franko A
    Radiol Oncol; 2019 Mar; 53(1):96-104. PubMed ID: 30840592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir.
    Jamwal RS; Mahajan N; Bhat GR; Bhat A; Shah R; Verma S; Sharma M; Sharma B; Qadri RA; Kumar R; Bhat A
    Cancer Epidemiol; 2021 Dec; 75():102047. PubMed ID: 34655923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.
    Varadi V; Bevier M; Grzybowska E; Johansson R; Enquist K; Henriksson R; Butkiewicz D; Pamula-Pilat J; Tecza K; Hemminki K; Lenner P; Försti A
    Breast Cancer Res Treat; 2011 Aug; 129(1):235-45. PubMed ID: 21455670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.
    Erčulj N; Kovač V; Hmeljak J; Dolžan V
    Ann Oncol; 2012 Apr; 23(4):961-7. PubMed ID: 21765044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translesion synthesis mechanisms depend on the nature of DNA damage in UV-irradiated human cells.
    Quinet A; Martins DJ; Vessoni AT; Biard D; Sarasin A; Stary A; Menck CF
    Nucleic Acids Res; 2016 Jul; 44(12):5717-31. PubMed ID: 27095204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma.
    Levpuscek K; Goricar K; Kovac V; Dolzan V; Franko A
    Radiol Oncol; 2019 Mar; 53(2):206-212. PubMed ID: 30893058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome Evolution Analysis of Recurrent Testicular Malignant Mesothelioma by Whole-Genome Sequencing.
    Zhang S; Zhang Q; Sun Q; Tang J; Chen J; Ji N; Zheng Y; Fang F; Lei W; Li P; Zhang N
    Cell Physiol Biochem; 2018; 45(1):163-174. PubMed ID: 29334678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
    Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
    Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.
    Štrbac D; Goričar K; Dolžan V; Kovač V
    Dis Markers; 2017; 2017():8069529. PubMed ID: 29138529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
    Lee MJ; Kuehne N; Hueniken K; Liang S; Rai S; Sorotsky H; Herman M; Shepshelovich D; Bruce J; Liang M; Patel D; Cheng D; Chen Z; Eng L; Brown MC; Cho J; Leighl NB; de Perrot M; Reisman D; Xu W; Bradbury PA; Liu G
    Mol Carcinog; 2019 Nov; 58(11):1960-1973. PubMed ID: 31355511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
    Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
    Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of REV3L promotes p53-regulated cancer cell metabolism in cisplatin-treated lung carcinoma cells.
    Kong L; Murata MM; Digman MA
    Biochem Biophys Res Commun; 2018 Jan; 496(1):199-204. PubMed ID: 29307819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
    Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
    Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
    Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S
    Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
    Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
    J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.